SEC Form 4 · accession 0001209191-17-005322
Karyopharm Therapeutics Inc. · KPTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Kauffman
Officer — Chief Executive Officer · Director
Period of report
Jan 20, 2017
Accepted (ET)
Jan 24, 2017 · 5:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $10.39 | Jan 20, 2017 | A | 250,000 | A | — | Jan 19, 2027 | Common Stock | 250,000 | 250,000 | D |
| Stock Option (right to buy)F1 | $10.39 | Jan 20, 2017 | A | 250,000 | A | — | Jan 19, 2027 | Common Stock | 250,000 | 250,000 | I |
Explanation of responses
- F1This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.